MVRBF Stock News 16.6200 05/08/2014 04:28:25 Medivir Ser B Sek5

New Post Public Reply Private Reply Replies (0) Message Board

May 8, 2014 at 5:28 AM

Medivir Ser B Sek5 (MVRBF) 16.6200 $MVRBF

Bone Metastasis - Pipeline Review, H1 2014: 20 Companies and 33 Drugs Profiled
M2 - 1 hr 11 mins ago
Research and Markets (http://www.researchandmarkets.com/research/7v66kz/bone_metastasis) has announced the addition of the "Bone Metastasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Bone Metastasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bone Metastasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bone Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Involved: - APT Therapeutics, Inc. - Alethia Biotherapeutics Inc. - AlphaMab Co., Ltd - Amgen Inc. - Amura Holdings Ltd. - Bayer AG - Celsion Corporation - Debiopharm International S.A. - Deciphera Pharmaceuticals, LLC - DexTech Medical AB - Digna Biotech, S.L. - Eli Lilly and Company - Johnson & Johnson - Medivir AB - Merrion Pharmaceuticals Plc - Osteologix Holdings Plc. - Sigma-Tau S.p.A. - TWi Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - Transgene SA Drug Profiles: - denosumab - denosumab - radium Ra 223 dichloride - zoledronic acid - MLN-1202 - doxorubicin liposomal - radium Ra 223 dichloride - Osteodex - MIV-711 - Debio-0719 - P-17 - disitertide - MIV-710 - SST-0001 - TG-3003 - AB-25E9 - AM-3701 - DCC-2909 - AC-301 - APT-102 - Secreted Phosphoprotein 24 KDa - Vicrostatin - ADM-01 - JNJ-28312141 - DP-6865 - LY-2109761 - LY-364937 - EGFR Inhibitors for Oncology - (paclitaxel PEG alendronate) For more information visit http://www.researchandmarkets.com/research/7v...metastasis

Alexza Pharmaceuticals reports availability of ADASUVE in the Nordic Countries for schizophrenia or bipolar disorder
M2 - Thu May 01, 6:35AM CDT
Alexza Pharmaceuticals (NasdaqGM:ALXA) revealed on Wednesday the market launch of ADASUVE inhalation powder, pre-dispensed (loxapine) in the Nordic countries (Sweden, Norway, Denmark and Finland) for the treatment of schizophrenia or bipolar disorder.

Alexza Pharmaceuticals Announces the Launch of ADASUVE® (inhalation powder, loxapine) in the Nordic Countries
PR Newswire - Wed Apr 30, 3:05PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that ADASUVE® inhalation powder, pre-dispensed (loxapine) is now available in the Nordic countries (Sweden, Norway, Denmark and Finland). Grupo Ferrer Internacional, S.A. ("Ferrer"

is commercializing ADASUVE in the Nordic countries through a distribution agreement with Medivir AB. Ferrer is Alexza's commercial partner for ADASUVE in the Europe, Latin America and the Commonwealth of Independent States countries.

Medivir: Adasuve will now be launched in Sweden, Norway, Finland and Denmark
Business Wire - Wed Apr 30, 6:17AM CDT
Regulatory News:

Global Dengue Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m3qq9r/dengue_pipeline) has announced the addition of the "Global Dengue Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - GenVec, Inc. - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - FIT Biotech Oyj - Biological E. Limited - Biotron Limited - Sarepta Therapeutics, Inc. - Medivir AB - NanoViricides, Inc. - SIGA Technologies, Inc. - Panacea Biotec Limited - Bharat Biotech International Limited - Protein Potential, LLC - TechnoVax, Inc. - MacroGenics, Inc. - PTC Therapeutics, Inc. - Chimerix, Inc. - Immunotope, Inc. - Immunovaccine, Inc. - VaxInnate Corporation - Janssen Pharmaceuticals, Inc. - Cocrystal Discovery, Inc. - PaxVax - AltraVax Inc. - Oneness Biotech Co., Ltd. - Arbovax, Inc. - Sanofi Pasteur SA - Themis Bioscience GmbH - Agilvax, Inc. - Humabs BioMed SA - Codagenix, Inc. Drug Profiles - Dengue Vaccine - DENVax - TetraVax-DV Vaccine-Admixture TV003 - Attenuated Tetravalent Lyophilized Dengue Vaccine - celgosivir hydrochloride - TetraVax-DV Vaccine-Admixture 1 - TetraVax-DV Vaccine-Admixture 2 - TetraVax-DV Vaccine-Admixture TV005 - V-180 - Dengue Vaccine - DENV-1 PIV - ST-148 - DengueCide - TVX-005 - Dengue Vaccine - AVI-6006 - Dengue Vaccine - DV2G460P - squalamine lactate - ST-610 - Dengue Fever Vaccine - Dengue Tetravalent Vaccine - Vaccine For Dengue - Dengue Vaccine - CLEC5A mAb - Dengue Virus Vaccines - Dengue Virus Vacine - Dengue Vaccine - GREDEN/V1-4 - Subunit Vaccine For Dengue - Dengue Vaccine - DEN-2-JE Virus Chimeric Plasmid Vaccine - Chimeric Live-Attenuated Dengue Vaccine - DENV-1/2 prM E Chimeric Vaccine - Vaccine For Dengue - Small Molecules to Inhibit Furin for Dengue - DV-2-DeltaGVII - DV-2-DeltaLIG - Mult. mAbs/DARTs - Small Molecule for Dengue - Vaccine For Dengue Fever - Small Molecule for Viral Infections - Small Molecule to Inhibit NS3 Protease for Dengue - Viral PMO-X - Small Molecule For Dengue - LCTA-949 - DiTU - BG-323 - Small Moleucles to Activate AMPK for Dengue - Small Molecules to Inhhibit Serine Protease for Viral Infections - Subunit Vaccine for Dengue Fever For more information visit http://www.researchandmarkets.com/research/m3...e_pipeline

HemoShear Enters into R&D Collaboration with Medivir
PR Newswire - Wed Apr 23, 6:00AM CDT
HemoShear, LLC, the human disease biology company, today announced research collaboration with Medivir AB of Stockholm, Sweden, an emerging research-based pharmaceutical company focused on infectious diseases. The collaboration will explore the application of HemoShear's platform in an undisclosed area of strategic interest. In this initial phase of the collaboration, HemoShear will characterize biological mechanisms and the effects of drug candidates on liver tissue using the Company's first-in-class human liver system. The HemoShear human liver system accurately replicates in vivo physiological conditions, enabling a more precise and definitive assessment of targets and drug candidates, drug-induced changes in biology and pharmacological responses.

Medivir: Good Market Uptake for Simeprevir During the First Quarter 2014
Business Wire - Tue Apr 15, 7:06AM CDT
Regulatory News:

Medivir: Final Data from the Phase II COSMOS Study with Simeprevir in Combination with Sofosbuvir Presented at EASL
Business Wire - Sat Apr 12, 11:06AM CDT
Regulatory News:

Notice of Annual General Meeting of Medivir AB (publ)
Business Wire - Mon Apr 07, 4:15AM CDT
Regulatory News:

Medivir: Annual Report 2013
Business Wire - Mon Apr 07, 2:51AM CDT
Regulatory News:

Medivir's Simeprevir approved for treatment in Russia
M2 - Mon Mar 24, 5:26AM CDT
Medivir AB (STO:MVIRB.ST), a research-based pharmaceutical company focused on infectious diseases, announced today the approval by the Russian Ministry of Health of Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection in combination with pegylated interferon and ribavirin in HCV genotype 1 and 4 infected patients with compensated liver disease, including cirrhosis.

Medivir: New Simeprevir data will be presented at The International Liver Congress 2014 of the European Association for the Study of the Liver, (EASL)
Business Wire - Mon Mar 24, 4:48AM CDT
Regulatory News:

Medivir: Simeprevir has now been approved in Russia
Business Wire - Mon Mar 24, 2:40AM CDT
Regulatory News:

Medivir: The Nomination Committee's Proposal, with Reference to the Upcoming 2014 Annual General Meeting, for a New Board of Directors
Business Wire - Fri Mar 14, 7:43AM CDT
Regulatory News:

Medivir: SVR12 Results from a Phase IIa Study Evaluating Simeprevir and Daclatasvir in Hepatitis C Patients of Genotype 1 Have Been Presented
Business Wire - Tue Mar 04, 11:30AM CST
Regulatory News:

Medivir reports profit in 2013
M2 - Mon Feb 24, 6:37AM CST
Swedish medical research company Medivir AB (STO:MVIRB.ST) reported today profit after tax of SEK16m, or SEK 0.51 per share, for the year 2013, from 1 January 2013 to 31 December 2013.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TDS Hits Bumps but Keeps Shareholders Happy

High Hopes and Hard Hits: TDS in 2026 Listen up, folks. Telephone and Data Systems, Inc. (NYSE: TDS) just popped the hood on their third quarter earnings, and it's a mixed bag with plenty to chew over. Operating revenues are slightly down from last year, but management's got some tricks up their sleeves. CEO Walter Carlson is trumpeting their expanded fiber service...

Ripple and AOF Triumph with Bronze Anthem Award Win

Small Businesses Find Their Voice with Ripple & AOF Accolades are sweet, but when they highlight real stories of change, you've got something more than just a shiny trophy. That's what's cooking over at Ripple and Accion Opportunity Fund (AOF) with their 'Unlocking Opportunity Together' campaign snagging a Bronze Anthem Award in the Humanitarian Action & Services...

Brookdale Shows Recovery with Improved Q3 2026 Results

Cracking Open Brookdale's Q3 2026 Numbers: A Mixed Bag You know, there's something oddly satisfying about net losses shrinking like a cheap wool sweater in a hot wash. Brookdale Senior Living's third quarter results show just that. We're looking at a net loss of $13.9 million, a big step up from the towering $114.7 million nosedive a year ago. Yeah, it's still a loss, but...

Silversea Opens World's Southernmost Hotel in Chile

Launching into the Frozen Frontier Roll out the red carpet—or should I say, the white one—because Silversea's just dropped a hospitality bombshell down at the ends of the Earth. The Cormorant at 55 South flung its doors wide open, setting Puerto Williams, Chile, in the limelight. And boy, it's making waves. We're talking about the southernmost hotel on this spinning...

Hyperstar's Bold Push: Sales Over Follower Hype

A New Era in Influencer Marketing: Hyperstar's Gamble Here's a kicker—follower count is starting to take the back seat, and it's about darn time. Over in Seoul, Hyperstar is shaking up the influencer marketing scene with a new laser focus: not who's got the biggest podium, but who can actually move the product. CEO Euychul Shin seems bent on rewriting the playbook. He...

Pendas Family Seeks Privacy After Helicopter Tragedy

A Family's Heartfelt Request in the Face of Tragedy Sometimes life deals in blows that are as sudden as they are incomprehensible. This is one of those times for the Pendas family. Tomas Pendas, a Miami native and the heart behind Global Air Group, tragically passed away in a helicopter crash on November 4th, 2026 near Nixon Beach in Biscayne Bay. Looking Back: Tomas...

CassTime's AI Solution Eases Global Parts Market Strains

Driving Innovation in the Auto Aftermarket When car parts become a global jigsaw puzzle, you need more than wrenches to solve it. Enter CassTime with its AI-driven 'T+D Solution'—a tangible answer to the woes of data matching and repair capability bottlenecks plaguing the automotive aftermarket worldwide. Taming the Global Parts Beast Pull back the curtain on AAPEX 2026...

Cognizant Grabs Wizeline: A Power Play in Digital

An Acquisition with Strategic Weight Cognizant's just bagged a beast, folks. The purchase of Wizeline marks a hefty step for NASDAQ:CTSH in the ever-evolving landscape of digital engineering and AI. It's not the kind of strategic move you see every day. The Wizeline Asset: What Stands Out? Wizeline isn't just window dressing. It's a heavy hitter in AI-native digital...

Beverly Hills Body Academy: A New Era in Contouring

Setting New Standards in Body Contouring It's no secret that Beverly Hills is all about luxury and cutting-edge trends. So, when the Beverly Hills Body Academy™ (BHBA) sets up shop in this glitzy locale, it's a pretty loud statement in the world of body contouring. This isn't just another vanity-driven operation; it's about pioneering advancements in the field of body...

U Power's H1 2026: Inside the Financial Numbers

Financial Struggles Amid Expansion Efforts Imagine a ship trying to lift anchor while taking on water. That's U Power Limited's latest financials for the first half of 2026 in a nutshell. We're seeing the company, listed under NASDAQ: UCAR, navigating through turbulent financial seas while executing ambitious expansion projects. Revenue Declines Spell Trouble Total net...